These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36191692)

  • 21. Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.
    Bailey AJ; Rhee SY; Shafer RW
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):736-743. PubMed ID: 33683148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
    Radzio-Basu J; Council O; Cong ME; Ruone S; Newton A; Wei X; Mitchell J; Ellis S; Petropoulos CJ; Huang W; Spreen W; Heneine W; García-Lerma JG
    Nat Commun; 2019 May; 10(1):2005. PubMed ID: 31043606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
    Abram ME; Hluhanich RM; Goodman DD; Andreatta KN; Margot NA; Ye L; Niedziela-Majka A; Barnes TL; Novikov N; Chen X; Svarovskaia ES; McColl DJ; White KL; Miller MD
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2654-63. PubMed ID: 23529738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
    Hachiya A; Kirby KA; Ido Y; Shigemi U; Matsuda M; Okazaki R; Imamura J; Sarafianos SG; Yokomaku Y; Iwatani Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
    Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
    BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
    Smith SJ; Zhao XZ; Burke TR; Hughes SH
    Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
    Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK
    J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy.
    Huik K; Hill S; George J; Pau A; Kuriakose S; Lange CM; Dee N; Stoll P; Khan M; Rehman T; Rehm CA; Dewar R; Grossman Z; Maldarelli F
    AIDS; 2022 Nov; 36(13):1835-1840. PubMed ID: 35848510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
    Parikh UM; Koss CA; Mellors JW
    Curr HIV/AIDS Rep; 2022 Oct; 19(5):384-393. PubMed ID: 36112336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
    Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
    Margot NA; Ram RR; White KL; Abram ME; Callebaut C
    J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir.
    Beck IA; Boyce CL; Bishop MD; Vu YL; Fung A; Styrchak S; Panpradist N; Lutz BR; Frenkel LM
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors.
    Yoshinaga T; Seki T; Miki S; Miyamoto T; Suyama-Kagitani A; Kawauchi-Miki S; Kobayashi M; Sato A; Stewart E; Underwood M; Fujiwara T
    Antiviral Res; 2018 Apr; 152():1-9. PubMed ID: 29410019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.
    Zhao AV; Crutchley RD; Guduru RC; Ton K; Lam T; Min AC
    Retrovirology; 2022 Oct; 19(1):22. PubMed ID: 36273165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.
    Eshleman SH; Fogel JM; Halvas EK; Piwowar-Manning E; Marzinke MA; Kofron R; Wang Z; Mellors J; McCauley M; Rinehart AR; St Clair M; Adeyeye A; Hinojosa JC; Cabello R; Middelkoop K; Hanscom B; Cohen MS; Grinsztejn B; Landovitz RJ;
    J Infect Dis; 2022 Dec; 226(12):2170-2180. PubMed ID: 36240386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
    Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.